Work at ILRI:We aim at producing an improved vaccine for East Cost fever (ECF) which is the most important cattle disease in East Africa. ILRI is currently leading an ECF consortium with components of identifying a suitable delivery systems, discovery of new CTL and antibody targets, sequencing of additional parasite strains, stage specific expression profiles etc.
Professional/Research Interests: Vaccine immunology, infectious diseases and cancer. Interactions of cytotoxic T Cell (CTL), T-helper cells and APC, CTL induction, improvement of responses by adjuvants, vaccine development.
Background: Lucilla has a background, since 1995, from the Biotech sector in Denmark where she worked in two different companies, Pharmexa A/S and later Symphogen A/S as research scientist, senior scientist and project manager. The work was concerned about human vaccine development and generation of therapeutic antibodies to various diseases. Beside this, she has been involved in various aspects of technology development projects leading to platform technologies for the companies. She received my PhD in 2001 in cellular immunology from University of Copenhagen, Denmark. This work was concerned about breaking of cytotoxic T Cell (CTL) tolerance, CTL induction and vaccine generation. Very early on she was employed at Hvidovre hospital in Denmark doing research in the Human immunodeficiency Virus (HIV) lab there.
Publications: 1. Werner T, Ferroni S, Saermark T, Brack-Werner R, Banati RB, Mager R, Steinaa L, Kreutzberg GW, Erfle V. HIV-1 Nef protein exhibits structural and functional similarity to scorpion peptides interacting with K+ channels.AIDS. 1991 Nov; 5(11):1301-8. 2. Steinaa L, Sorensen AM, Nielsen JO, Hansen JE. Antibody to HIV-1 Tat protein inhibits the replication of virus in culture.Arch Virol. 1994; 139(3-4):263-71.
<p>3. Steinaa L, Wulff AM, Saermark T. Monoclonal antibodies against a synthetic peptide from human immunodeficiency virus type 1 Nef protein.Hybridoma. 1994 Oct; 13(5):383-8. 4. Spetzler JC, Meldal M, Meinjohanns E, Steinaa L, Mouritsen S, Bock K. Synthetic hFSH peptide constructs in the evaluation of previous studies on the hFSH receptor interaction. J Pept Sci.1997 Nov-Dec; 3(6):397-414. 5. Dalum I, Butler DM, Jensen MR, Hindersson P, Steinaa L, Waterston AM, Grell SN, Feldmann M, Elsner HI, Mouritsen S. Therapeutic antibodies elicited by immunization against TNF-alpha.Nat Biotechnol. 1999 Jul; 17(7):666-9. 6. Jensen, MR, Dalum I, Steinaa L, Balschen T, Harris AS, Mourisen S. Immunization against TNFa - a new approach for the treatment of inflammatory bowel disease. Gastroenterology 2000: 118(4): 85634-6. 7. Steinaa L, Rasmussen PB, Wegener AM, Sonderbye L, Leach DR, Rygaard J, Mouritsen S, Gautam AM. Linked foreign T-cell help activates self-reactive CTL and inhibits tumor growth. J Immunol. 2005 Jul 1; 175(1):329-34. 8. Meijer PJ, Andersen PS, Haahr Hansen M, Steinaa L, Jensen A, Lantto J, Oleksiewicz MB, Tengbjerg K, Poulsen TR, Coljee VW, Bregenholt S, Haurum JS, Nielsen LS. Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J Mol Biol. 2006 May 5; 358(3):764-72. 9. Steinaa L, Rasmussen PB, Rygaard J, Mouritsen S, Gautam A. Generation of autoreactive CTL by tumour vaccines containing foreign T helper epitopes. Scand J Immunol. 2007 Mar; 65(3):240-8. 10. Steinaa L, Rasmussen PB, Gautam A., Mouritsen S. Breaking B-cell tolerance and CTL tolerance in three OVA-transgenic mouse strains expressing different levels of OVA". Scan J Immunol. 2008 Feb; 67(2):113-20. 11. Lantto J, Haahr Hansen M, Rasmussen SK, Steinaa L, Poulsen TR, Duggan J, Dennis M, Naylor I, Easterbrook L, Bregenholt S, Haurum J, Jensen A. Capturing the natural diversity of the human antibody response against vaccinia virus. J Virol 2011 Feb; 85(4):1820-33. 12. Koefoed K, Steinaa L, Søderberg JN, Christensen IK, Meijer P-J, Haurum JS, Jensen A, Krag M Andersen PS, Pedersen MW. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor MAbs 2011 Nov-Dec;3(6):584-95. 13. Steinaa L, Saya R, Awino E, Toye P. Cytotoxic T lymphocytes from cattle immunized against Theileria parva exhibit pronounced cross-reactivity among different strain-specific epitopes of the Tp1 antigen. Vet Immunol Immunopathol 2012 Feb 15;145(3-4):571-81. 14. Svitek N, Hansen AM, Steinaa L, Saya R, Awino E, Nielsen M., Buus S., Nene V. Use of "one-pot, mix-and-read" peptide-MHC class I tetramers and predictive algorithms to improve detection of cytotoxic T lymphocyte responses in cattle. Vet Res 2014, 45:50 15. Wendoh J, Waihenya R, Awino, S, Nene V., Steinaa L. Perforin expression in Theileria parva specific cytotoxic T cells correlates with cytotoxicity. OJI 2014, 4, 117-127. 16. Svitek N, Nzau B, Awino E, Steinaa L, Nene V. A method to discriminate between closely related bovine major histocompatibility complex class I alleles by combining established PCR-SSP assays with RFLPs. Tissue Antigens. Accepted. 17. Svitek N, Taracha EL, Saya R, Awino E, Nene V, Steinaa L. Analysis of the cellular immune responses to vaccines. In “Vaccine Technologies for Veterinary Viral Diseases”, Methods in Molecular Biology, Humana Press (Invited review; submitted). 18. Svitek N, Awino A, Saya R., Nene V, Steinaa L. BoLA 6*01301 and 6*01302, two allelic variants of the A18 haplotype, present the same epitope from the Tp1 antigen of Theileria parva. Ready for submission.
Patents: 15 (8 selected): 1. Steinaa L, Mouritsen S (+7). Pharmexa A/S. Novel methods for therapeutic vaccination. US2004141958 (2004). 2. Steinaa L, Mouritsen S (+7). Pharmexa A/S. Novel methods for therapeutic vaccination. US 20060008465 (2006). 3. Steinaa L, Mouritsen S (+7). Pharmexa A/S. Methods for therapeutic vaccination. EP1117421 B1 (2004). 4. Steinaa L, Mouritsen (+7). Pharmexa A/S. Methods for vaccination. US7005498 (B1). 2006 5. Steinaa L, Renard V. PHARMEXA A/S. Immunogenic EGFR peptides comprising foreign T cell stimulating epitope. US2008253993 (A1) - 2008 6. Jensen A., Lantto J., Hansen MH., Rasmussen LK., Rasmussen S., Steinaa L. Symphogen A/S.Anti-orthopoxvirus recombinant polyclonal antibody US2011158984 (A1). 2011. 7. Lantto, J, Steinaa L, Nielsen LS (+3). Symphogen A/S. Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections. US2010040606 (A1) 2010. 8. Pedersen MW, Steinaa L (+6). Symphogen A/S. Recombinant anti-epidermal growth factor receptor antibody compositions. ZA200905341 (A) 2010.